Cisplatin combined with the new cisplatin-procaine complex DPR: In vitro and in vivo studies

European Journal of Cancer Part A

Volumn 32, Issue 13, 1996, Pages 2327-2333

  Viale, M ^a   Vannozzi, M O ^a   Merlo, F ^a   Cafaggi, S ^b   Parodi, B ^b   Esposito, M ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Cisplatin; Cisplatin procaine complex; Combined action in vitro and in vivo

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; CISPLATIN PROCAINE COMPLEX; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR GROWTH;

EID: 0030446475     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00354-1     Document Type: Article

References (18)

1. 1. Cafaggi S, Esposito M, Vannozzi MO, et al. Synthesis and antitumour activity of a new cis-diammineplatinum(II) complex containing procaine hydrochloride. Anticancer Res 1992, 12, 2285-2292.
2. 2. Viale M, Cafaggi S, Parodi B, Esposito M. Cytotoxicity and cellular accumulation of a new cis-diammineplatinum(II) complex containing procaine in murine L1210 cells sensitive and resistant to cis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol 1995, 35, 371-376.
3. 3. Perez RP, Perez KM, Handel LM, Hamilton TC. In vitro interaction between platinum analogues in human ovarian-carcinoma cell lines. Cancer Chemother Pharmacol 1992, 29, 430-434.
4. 4. Los G, Tuyt L, van Vugt M, Schornagel J, Pinedo HM. Combination treatment of cis-and carboplatin in cancer restricted to the peritoneal cavity in the rat. Cancer Chemother Pharmacol 1993, 32, 425-433.
5. 5. Hussain RF, Noun AME, Oliver RTD. A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Meth 1993, 160, 89-96.
6. 6. Arakawa H, Iguchi T, Morita M, et al. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7(6H)-dione (NB-506): its potent antitumour activities in mice. Cancer Res 1995, 55, 1316-1320.
7. 7. Berenbaum MC. What is synergy? Pharmacol Rev 1989, 41, 93-141.
8. 8. Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 1981, 35, 269-335.
9. 9. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
10. 10. Breslow N. A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship. Biometrika 1970, 57, 579-594.
11. 11. Dixon JW. BMDP statistical software. Berkeley, University of California Press, 1983.
12. 12. Esposito M, Fulco RA, Collecchi P, et al. Improved therapeutic index of cisplatin by procaine hydrochloride. J Natl Cancer Inst 1990, 82, 677-684.
13. 13. Viale M, Melioli G, Pasquetti W, Meta M, Cafaggi S, Esposito M. Modifications of cell cycle induced by DPR, a new platinum-triamine complex containing procaine. Int J Oncol 1994, 4, 1047-1051.
14. 14. Los G, Verdegaal E, Noteborn H, et al. Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. Biochem Pharmacol 1991, 42, 357-363.
15. 15. Knox R, Friedlos F, Lydall D, Roberts J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxilato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986, 46, 1972-1979.
16. +. J Med Chem 1989, 32, 128-136.
17. 17. Hollis LS, Sundquist WI, Burstyn JN, Stern EW, Lippard SJ. Mechanistic studies of a novel class of trisubstituted platinum(II) antitumor agents. Cancer Res 1991, 51, 1866-1875.
18. 2+-modified DNA: rates of cross-linking reactions in cis-platinum-modined DNA. Nucleic Acids Res 1993, 21, 5846-5851.